Evofem Biosciences Operating Income 2013-2022 | EVFM

Evofem Biosciences operating income from 2013 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Evofem Biosciences Annual Operating Income
(Millions of US $)
2021 $-167
2020 $-104
2019 $-53
2018 $-78
2017 $-36
2016 $-12
2015 $-42
2014 $-10
2013 $-14
2012 $-6
Evofem Biosciences Quarterly Operating Income
(Millions of US $)
2022-03-31 $-29
2021-12-31 $-37
2021-09-30 $-43
2021-06-30 $-41
2021-03-31 $-45
2020-12-31 $-36
2020-09-30 $-26
2020-06-30 $-22
2020-03-31 $-19
2019-12-31 $-13
2019-09-30 $-14
2019-06-30 $-12
2019-03-31 $-14
2018-12-31 $-15
2018-09-30 $-18
2018-06-30 $-23
2018-03-31 $-21
2017-12-31 $-15
2017-09-30 $-9
2017-06-30 $-6
2017-03-31 $-5
2016-12-31 $-2
2016-09-30 $-2
2016-06-30 $-3
2016-03-31 $-6
2015-12-31 $-9
2015-09-30 $-17
2015-06-30 $-9
2015-03-31 $-7
2014-12-31 $-3
2014-09-30 $-2
2014-06-30 $-2
2014-03-31 $-2
2013-12-31
2012-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.011B $0.008B
Evofem Biosciences Inc. develops and anticipates commercializing products which support and promote women as the primary healthcare consumer. The company is identifying and developing new and novel products which specifically address unmet needs in the areas of sexual and reproductive health, the prevention of acquisition of sexually transmitted infections and products which address or promote general health and wellbeing. Evofem Biosciences Inc., formerly known as Neothetics Inc., is based in SAN DIEGO CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00